Viewing Study NCT03913559


Ignite Creation Date: 2025-12-24 @ 2:28 PM
Ignite Modification Date: 2026-02-25 @ 4:50 AM
Study NCT ID: NCT03913559
Status: RECRUITING
Last Update Posted: 2025-07-03
First Post: 2019-04-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
Sponsor: St. Jude Children's Research Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module